period of the prior year as detailed hereunder, 1. Revenues from sales of real estate, in the period for nine-month ended September 30, 2018, accumulated amount of 8,837.2 million baht, or 82.6% from the
50.91 percent of the total issued shares of the Company. The granting of loan as detailed above constitutes a connected transaction as it is an entering into a transaction with a major shareholder of the
, or 10.1% compared on the same period from last year as detailed hereunder, 1. Revenues from sales of real estate, in the period of Quarter3/2019, amount of 3,153.6 million baht, or 86.9% from the total
Company’s auditor. The conclusion was detailed as follows: The Company's operating results and its subsidiaries for the third quarter of 2019, the consolidated financial statements showed the net profit of
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for
ongoing outbreak of COVID–19, forcing many customers to adjust their working method which have an effect on the operation and delivery of the Company's projects that cause the operation to be delayed than
reducing production cost and also negotiating with customers to review and adjust selling price every quarter. 2.2. Distribution costs for 2018 was in the amount of 4.95 million baht, increased by 1.16
with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for certain expenses that the
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change